Document is current

Article History

Received: 4 February 2026

Accepted: 2 March 2026

First Online: 1 April 2026

Declarations

:

: Ethical approval was not required.

: NRF has received speaker fees and honoraria from Amgen, Echolight, UCB and Viatris and travel bursaries from Pfizer and Eli Lilly. FR has received speaker fees and honoraria from Grünenthal, IPSEN, Laboratoires Expanscience, IBSA-Genévrier, Servier, Pierre Fabre, Mylan, Ceformed. FB reports personal fees from 4P Pharma, 4Moving Biotech, Grunenthal, GSK, Heel, Nordic Bioscience, Novartis, Servier, TRB Chemedica, Viatris. MLB declares Honoraria from Amgen, Ascendis, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, grants and/or speaker fees from Alexion, Amgen, Amolyt, Bruno Farmaceutici, CoGeDi, Echolight, Gedeon Richter, Kyowa Kirin, Monte Rosa Therapeutics, UCB and consultancy for Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Echolight, Enterabio, Kyowa Kirin, Personal Genomics, Septern. OB has received consulting or lecture fees from Amgen, Aptissen, Biophytis, IBSA, Mylan, Novartis, Nutricia, Orifarm, Sanofi, UCB and Viatris. EMD reports honoraria from UCB, Viatris and Pfizer. ME reports consultancy for Grünenthal Sweden AB and Key2Compliance. NCH reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, UCB, Kyowa Kirin, Servier, Shire, Consilient Healthcare, Theramex and Internis Pharma. RR has received fees for advisory board or lectures from Abiogen, Effryx and Theramex. JYR reports consulting fees, Advisory Boards and/or speakers bureau for IBSA-Genevier, Mylan and TRB. AM has received speaker fees and honoraria from Sanofi, Sanofi CHC / Opella, Viatris, GSK, HALEON, Aptissen, Contura, Laboratoires Expanscience, ACI, Sunac Therapeutics, Ampio Pharmaceuticals, Synartro, Bruder Consulting and Venture Group, McKinsey and Company, Chiron, Chondropeptix, Grünenthal, Hypera Pharma, ICM, Kangstem, Kolon Life Science, Kolon TissueGene, Nestlé Health Science, Pluri, Enlivex, Apos Health, Pacira Biosciences, BioSplice, Genascence, California Institute for Regenerative Medicine, SynOA Therapeutics, Sporlastic GmbH, Rottapharm Biotechnology, and IBSA. All other authors have no conflict to declare.